Based on the current knowledge of the impact of the NLRP3 inflammasome on potential cancer promotion and therapy, studies are currently being done to determine the efficacy and safety of oral nutritional solution supplementation in patients with esophageal cancer. Here, NLRP3 is linked to esophageal cancer.